Benchmark lowered the firm’s price target on Agilon Health (AGL) to $1.50 from $4 and keeps a Buy rating on the shares. The stock was “cut roughly in half yesterday” after Agilon reported a wide Q2 miss, suspended FY25 guidance, and announced that CEO Steven Sell had stepped down, the analyst noted. Given the “positive trends still in place for 2026,” and with the stock now selling just slightly above cash per share, the firm reduced its target but maintains a Buy rating.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGL:
- Agilon Health price target lowered to $1 from $4 at TD Cowen
- Agilon Health Reports Q2 2025 Results Amid Leadership Change
- Agilon Health downgraded to Neutral from Buy at Citi
- Optimistic Buy Rating for Agilon Health Amid Strategic Initiatives and Future Prospects
- Agilon Health’s Hold Rating Amid CEO Resignation and Earnings Shortfall